BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33931379)

  • 1. Leukemic Stem Cell (CD34
    Mohamed MMI; Aref S; Agdar MA; Mabed M; El-Sokkary AMA
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):508-513. PubMed ID: 33931379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
    Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34
    Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Moshaver B; Wouters RF; Kelder A; Ossenkoppele GJ; Westra GAH; Kwidama Z; Rutten AR; Kaspers GJL; Zweegman S; Cloos J; Schuurhuis GJ
    Leuk Res; 2019 Jun; 81():27-34. PubMed ID: 31002948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M; Zeijlemaker W; Kelder A; Rutten AP; Snel AN; Scholten WJ; Pabst T; Verhoef G; Löwenberg B; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway.
    Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL
    Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotyping and Target Expression Profiling of CD34
    Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
    Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ; Meel MH; Wouters F; Min LA; Terwijn M; de Jonge NA; Kelder A; Snel AN; Zweegman S; Ossenkoppele GJ; Smit L
    PLoS One; 2013; 8(11):e78897. PubMed ID: 24244383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
    Kornblau SM; Qutub A; Yao H; York H; Qiu YH; Graber D; Ravandi F; Cortes J; Andreeff M; Zhang N; Coombes KR
    PLoS One; 2013; 8(10):e78453. PubMed ID: 24223100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
    Wang L; Gao L; Xu S; Gong S; Chen L; Lü S; Chen J; Qiu H; Xu X; Ni X; Song X; Zhang W; Yang J; Liu M; Hu X; Wang J
    J Hematol Oncol; 2013 Nov; 6(1):85. PubMed ID: 24517186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
    Gerber JM; Smith BD; Ngwang B; Zhang H; Vala MS; Morsberger L; Galkin S; Collector MI; Perkins B; Levis MJ; Griffin CA; Sharkis SJ; Borowitz MJ; Karp JE; Jones RJ
    Blood; 2012 Apr; 119(15):3571-7. PubMed ID: 22262762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
    Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
    Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.